From Viktar Lebedz, HAE Belarus
A year ago, in December 2022, updated official protocols for treating HAE attacks were approved. For the first time, C1 inhibitor drugs and lanadelumab were included in the treatment guidelines.
Starting from January 1, 2024, the updated document “List of Essential Medicines” comes into effect, which includes the C1 inhibitor drug CINRYZE®. The inclusion of CINRYZE® in this list means that patients with HAE can be provided with the medication at the expense of state funds.
Access to Effective HAE Medicine: Currently, in Belarus, there are two effective HAE medications registered: CINRYZE® and TAKHZYRO®.
Since 2020, purchases of the C1 inhibitor drug have been regularly made for pediatric patients with HAE: Berinert (2020, 2021), CINRYZE® (2022, 2023).
Starting in 2022, three adult HAE patients receive TAKHZYRO® prophylactically (monthly). The treatment is planned to be continued in 2024.
In 2023, a one-time purchase of CINRYZE® (a few doses for each patient) was made for two adult patients with HAE.
